David Chang, Allogene (Jeff Rumans)

Al­lo­gene spot­lights their off-the-shelf CAR-T con­tender ‘501 with a snap­shot on CRs and no GVHD

Al­lo­gene ex­ecs are out to rev­o­lu­tion­ize a field they played a ma­jor role in pi­o­neer­ing. And they will ar­rive — vir­tu­al­ly — at AS­CO with some sol­id ev­i­dence that they are on the right track.

The drug in the spot­light to­day is AL­LO-501, which re­searchers are putting through their paces in a Phase I tri­al for re­lapsed/re­frac­to­ry non-Hodgkin lym­phoma, in com­bi­na­tion with their oth­er in-house drug AL­LO-647 to di­rec­tion lym­phode­ple­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.